37 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
research, partially offset by decreased manufacturing costs.
General and administrative expenses were $13.5 million for the year ended December 31, 2023 … and equity-based compensation, partially offset by decreased Director & Officer Liability insurance and other expenses.
The Company reported a net loss
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
the disposition, which may be offset by certain U.S.-source capital losses of the Non-U.S. Holder, if any; or
our common stock constitute U.S. real
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
treaty between the United States and such holder’s country of residence) on the net gain derived from the disposition, which may be offset by certain
8-K
EX-99.1
ilcle
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
h75of48yekp8wnj
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
x8l2 97dy51brwxys
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
424B4
sy9unl 3x0rl8v7h
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
jz97y8k2sex8igg
20 Oct 22
Draft registration statement
12:00am
8-K
EX-99.1
jmg6rzi5bv1yz 69efvw
9 Aug 22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
7:15am
8-K
EX-99.1
eudr1z
11 May 22
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
7:06am
10-K
52g540gf8 lev
30 Mar 22
Annual report
7:40am